Can Non-Obstructive HCM Become Obstructive Over Time?
At a Glance
Yes, non-obstructive hypertrophic cardiomyopathy (HCM) can become obstructive over time due to gradual heart thickening or valve changes. Patients should have regular echocardiograms and watch for new symptoms like shortness of breath or dizziness, which may signal a developing blockage.
Yes, non-obstructive hypertrophic cardiomyopathy (HCM) can become obstructive over time. While the majority of people with the non-obstructive subtype experience a stable condition for years and never develop a blockage [1], HCM is a dynamic disease. Over time, structural changes in the heart can cause the blood flow out of the left ventricle to become blocked, a condition known as left ventricular outflow tract (LVOT) obstruction [2][3].
How Does Obstruction Develop Later in Life?
The shift from non-obstructive to obstructive HCM generally happens due to heart remodeling—gradual physical changes in the heart muscle and its surrounding structures:
- Progressive Thickening: The heart muscle—especially the septum, the wall separating the left and right sides of the heart—may continue to thicken very slowly over the years [4]. If it becomes thick enough, it can intrude into the outflow tract and physically block blood flow [5].
- Mitral Valve Changes: The mitral valve controls blood flow between the left chambers of the heart. Over time, the valve leaflets can stretch or the structures holding them in place can shift. These anatomical changes can cause the valve to be sucked into the outflow tract when the heart beats, creating an obstruction [6]. Cardiologists refer to this specific valve movement as Systolic Anterior Motion (SAM).
- Age-Related Geometry Changes: As people age, the overall shape and size of the heart cavity can change. A smaller left ventricular cavity combined with age-related changes can alter the internal pressure of the heart, promoting an obstruction [4].
The Hidden Obstruction: “Latent” HCM
While an obstruction can newly develop as your heart remodels, sometimes it was already there but simply hidden during standard testing [7]. This is known as latent obstruction.
A standard echocardiogram (ultrasound of the heart) is performed while you are lying down and resting. If you only have an obstruction when your heart is working hard, your resting echocardiogram will show “non-obstructive” HCM [8]. If you experience symptoms like shortness of breath or dizziness during physical activity, doctors will use an exercise stress echocardiogram to see if an obstruction is triggered by physical exertion [9][10].
Furthermore, daily triggers such as dehydration, heavy meals, or drinking alcohol can temporarily reduce the amount of blood in the heart chamber, bringing the walls closer together and worsening a hidden obstruction.
Why Regular Surveillance is Critical
Because the physical characteristics of your heart can change, regular monitoring is essential. Current medical guidelines recommend regular, ongoing surveillance with imaging tools like echocardiograms [11][12].
For stable, non-obstructive adult patients, this typically means having an echocardiogram every 1 to 2 years, though your doctor will tailor this timeline to your specific case. Routine echocardiograms allow your care team to measure the thickness of your heart walls, look for signs of Systolic Anterior Motion (SAM), and check the blood flow dynamics to catch any signs of newly developing obstruction [11][10].
When to call your doctor: Do not wait for your next scheduled echocardiogram if you notice new or worsening symptoms. Shortness of breath, chest pain, dizziness, or feeling faint—especially during activity—are red flags that an obstruction may be developing and should be evaluated promptly.
A Shift in Treatment
Knowing whether your HCM has become obstructive is important because it changes your treatment plan. If you transition to obstructive HCM and develop symptoms, your doctor will adjust your care to focus on relieving the blockage and helping your heart relax [13].
This typically begins with standard medications like beta-blockers or calcium channel blockers. If symptoms persist, your doctor might add newer cardiac myosin inhibitors (medications specifically designed to relax the hyperactive heart muscle). In advanced cases where medications are not enough, you may discuss procedures to physically reduce the thickness of the septum, such as Septal Myectomy (open-heart surgery to remove muscle) or Alcohol Septal Ablation (a minimally invasive procedure to shrink the muscle) [14].
The Good News: Even if your condition does become obstructive, it is highly treatable. Modern medications and procedures are incredibly effective at relieving the blockage and restoring a normal quality of life.
Common questions in this guide
Can non-obstructive HCM turn into obstructive HCM?
What is a latent HCM obstruction?
What are the warning signs that my HCM is becoming obstructive?
How does treatment change if my HCM becomes obstructive?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Have I ever had an exercise stress echocardiogram to rule out a hidden (latent) obstruction?
- 2.Based on my current heart structure, such as the thickness of my septum or my mitral valve anatomy, am I at a higher risk for developing an obstruction over time?
- 3.How often do you recommend we perform routine surveillance echocardiograms for my specific case?
- 4.Do you see any signs of Systolic Anterior Motion (SAM) on my past echocardiogram reports?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
[Clinical and genetic characteristics of different types of non-obstructive hypertrophic cardiomyopathy].
Zhang M, Sun XL, Wu GX, et al.
Zhonghua xin xue guan bing za zhi 2021; (49(6)):593-600 doi:10.3760/cma.j.cn112148-20210118-00056.
PMID: 34126727 - 2
Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology.
Li-Wen Chu E, Seung Kim D, Masri A
Cardiac failure review 2025; (11()):e27 doi:10.15420/cfr.2025.08.
PMID: 41234531 - 3
Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy.
Kumar S, Van Ness G, Bender A, et al.
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2018; (31(7)):791-798 doi:10.1016/j.echo.2018.01.022.
PMID: 29573929 - 4
Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy.
Teo EP, Teoh JG, Hung J
Current opinion in cardiology 2015; (30(5)):475-82 doi:10.1097/HCO.0000000000000200.
PMID: 26192489 - 5
Comprehensive left ventricular outflow tract management beyond septal reduction to relieve obstruction.
Gharibeh L, Smedira NG, Grau JB
Asian cardiovascular & thoracic annals 2022; (30(1)):43-52 doi:10.1177/02184923211034689.
PMID: 34605271 - 6
Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography.
Patel P, Dhillon A, Popovic ZB, et al.
Circulation. Cardiovascular imaging 2015; (8(7)):e003132 doi:10.1161/CIRCIMAGING.115.003132.
PMID: 26082555 - 7
Sitting maneuver to uncover latent left ventricular outflow tract obstruction in patients without hypertrophic cardiomyopathy.
Sekine A, Watanabe T, Nakabo A, et al.
Journal of cardiology 2024; (83(6)):401-406 doi:10.1016/j.jjcc.2023.11.006.
PMID: 38000537 - 8
Obstructive Hypertrophic Cardiomyopathy and Takotsubo Syndrome: How to Deal With Left Ventricular Ballooning?
Citro R, Bellino M, Merli E, et al.
Journal of the American Heart Association 2023; (12(21)):e032028 doi:10.1161/JAHA.123.032028.
PMID: 37889174 - 9
Role of Exercise Testing in Hypertrophic Cardiomyopathy.
Rowin EJ, Maron BJ, Olivotto I, Maron MS
JACC. Cardiovascular imaging 2017; (10(11)):1374-1386 doi:10.1016/j.jcmg.2017.07.016.
PMID: 29122139 - 10
The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications.
Rowin EJ, Maron BJ, Maron MS
JACC. Cardiovascular imaging 2020; (13(9)):2002-2016 doi:10.1016/j.jcmg.2019.09.020.
PMID: 31864978 - 11
Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.
Banthiya S, Check L, Atkins J
US cardiology 2024; (18()):e17 doi:10.15420/usc.2023.21.
PMID: 39508003 - 12
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.
Maron BJ, Desai MY, Nishimura RA, et al.
Journal of the American College of Cardiology 2022; (79(4)):372-389 doi:10.1016/j.jacc.2021.12.002.
PMID: 35086660 - 13
Obstruction in Hypertrophic Cardiomyopathy: Many Faces.
Abbasi M, Ong KC, Newman DB, et al.
Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2024; (37(6)):613-625 doi:10.1016/j.echo.2024.02.010.
PMID: 38428652 - 14
Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
Chase Cole J, Benvie SF, DeLosSantos M
Clinical therapeutics 2024; (46(4)):368-373 doi:10.1016/j.clinthera.2024.02.007.
PMID: 38508915
This page provides educational information about the progression of hypertrophic cardiomyopathy. Always consult your cardiologist to understand your specific heart anatomy, risk of obstruction, and appropriate surveillance schedule.
Get notified when new evidence is published on Hypertrophic Cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.